Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Cowen

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by research analysts at TD Cowen from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

MIST has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Friday, March 28th. TD Securities cut shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday.

Milestone Pharmaceuticals Stock Up 5.7 %

Shares of NASDAQ:MIST opened at $0.80 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a 52-week low of $0.71 and a 52-week high of $2.75. The business’s 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $1.82. The firm has a market cap of $42.85 million, a P/E ratio of -0.99 and a beta of 1.83.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in MIST. Toronto Dominion Bank bought a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth approximately $1,770,000. Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals in the fourth quarter worth $729,000. Virtu Financial LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at $170,000. XTX Topco Ltd purchased a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth about $80,000. Finally, Cubist Systematic Strategies LLC bought a new position in Milestone Pharmaceuticals during the fourth quarter valued at about $73,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.